Psychological Mechanisms in Psychedelic-Assisted Therapy for SUDs: 2026 Scoping Review

Scoping Review Maps Six Psychological Mechanisms in PAT for SUDs

A comprehensive scoping review published in September 2026 synthesizes current evidence on the psychological mechanisms underpinning psychedelic-assisted therapy (PAT) for substance use disorders (SUDs). Drawing from 37 peer-reviewed publications representing 23 unique cohorts (n = 1003), the review identifies six transdiagnostic domains through which PAT may facilitate behavioral change: emotional processing, insight and meaning-making, self-experience and identity transformation, mystical or peak-type experiences, relational and interpersonal shifts, and motivation, values, and behavioral regulation. Both classical psychedelics (psilocybin, ayahuasca) and non-classical compounds (ketamine, MDMA, ibogaine) are included, reflecting the diversity of substances under investigation for SUDs.

Mystical Experiences and Other Mechanisms: Evidence and Context

Mystical-type or peak experiences emerge as the most frequently studied mechanism, with consistent associations reported between these experiences and reductions in substance use or cravings. However, the review notes that evidence remains largely correlational, with only a single randomized trial demonstrating mediation of substance use outcomes by mystical experience. Other mechanisms—such as emotional processing, shifts in self-concept, and enhanced motivation—are supported by qualitative and exploratory quantitative findings. Notably, the review highlights that these psychological processes are not isolated; rather, they interact in complex ways, shaped by the therapeutic setting, the therapeutic relationship, and broader sociocultural context. This underscores the importance of context in translating acute psychedelic experiences into meaningful behavioral change.

• Emotional Processing: Enhanced emotional awareness and processing during and after sessions may reduce avoidance patterns linked to substance use.
• Insight and Meaning-Making: Sessions often yield new perspectives on life, addiction, and personal values, potentially supporting recovery motivation.
• Identity Transformation: Shifts in self-concept or worldview are frequently reported, sometimes described as a sense of 'reset.'
• Relational Shifts: Improved interpersonal connections and empathy may support social support systems, a known protective factor in SUD recovery.

Policy and Research Implications: The Need for Causal Evidence

The review's findings have direct implications for research design, clinical protocols, and regulatory policy. Despite growing interest in PAT for SUDs, most studies to date are qualitative or correlational, limiting the ability to draw firm conclusions about causality. The authors call for more rigorous, mechanism-focused randomized controlled trials (RCTs) that explicitly test whether changes in specific psychological domains mediate substance use outcomes. This is a critical step for regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which increasingly require mechanism-based evidence to inform approval and labeling decisions. Notably, the review also points out that optimizing PAT protocols may require tailoring interventions to target specific psychological processes, rather than relying on a one-size-fits-all approach.

An underappreciated insight from the review is the potential for failure modes if context is neglected: for instance, mystical experiences without adequate integration support may not translate into sustained behavioral change, or could even exacerbate distress in vulnerable populations. This suggests that future policy and funding decisions should prioritize research into integration protocols and therapist training, not just the pharmacological component.

Risks, Unknowns, and the Path Forward

While the review highlights promising associations between PAT and reductions in substance use, it also underscores significant unknowns and risks. The evidence base remains preliminary, with few large-scale, well-controlled trials. There is a risk of over-attributing efficacy to mystical experiences or other acute effects, when long-term outcomes may depend on less visible, context-dependent processes. Additionally, the review notes that most studies have focused on select populations and may not generalize across diverse demographic or clinical groups. Adverse psychological reactions, such as challenging experiences or increased psychological distress, are also underreported in the current literature. For clinicians and policymakers, this means that caution and robust monitoring are warranted as PAT expands into broader clinical practice.

Looking Ahead: Building a Nuanced Evidence Base

The 2026 scoping review provides a valuable roadmap for the next generation of PAT research and practice. Clarifying the causal mechanisms of action—across both substances and populations—will be essential for optimizing treatment protocols and ensuring safe, effective implementation. For researchers, this means designing trials that can disentangle the contributions of acute psychedelic effects, therapeutic context, and integration processes. For regulators and funders, the findings suggest a need to support mechanism-driven research and to develop guidance on best practices for integration and therapist training. As the field moves forward, a nuanced, context-aware approach will be key to realizing the potential—and managing the risks—of psychedelic-assisted therapy for substance use disorders.

Reviewed by Dr. Alex Harper, PhD (Neuroscience). How we research: This article was prepared using direct analysis of the original scoping review (OpenAlex: W7204988578, published 2026-09-02), with additional context from regulatory agency guidelines and clinical trial registries. Reviewed on 2026-09-06.